Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.
Medpage Today on MSN4d
Inching Toward a Blood Test for Hypertrophic CardiomyopathyHCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...
BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...
The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...
A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.
Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...
Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback